Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Open accessThe DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Abstract
The "Amyloid Cascade Hypothesis" has dominated the Alzheimer's disease (AD) field in the last 25 years. It posits that the increase of amyloid-β (Aβ) is the key event in AD that triggers tau pathology followed by neuronal death and eventually, the disease. However, therapeutic approaches aimed at decreasing Aβ levels have so far failed, and tau-based clinical trials have not yet produced positive findings. This begs the question of whether the hypothesis is correct. Here we have examined literature on the role of Aβ and tau in synaptic dysfunction, memory loss, and seeding and spreading of AD, highlighting important parallelisms between the two proteins in all of these phenomena. We discuss novel findings showing binding of both Aβ and tau oligomers to amyloid-β protein precursor (AβPP), and the requirement for the presence of this protein for both Aβ and tau to enter neurons and induce abnormal synaptic function and memory. Most importantly, we propose a novel view of AD pathogenesis in which extracellular oligomers of Aβ and tau act in parallel and upstream of AβPP. Such a view will call for a reconsideration of therapeutic approaches directed against Aβ and tau, paving the way to an increased interest toward AβPP, both for understanding the pathogenesis of the disease and elaborating new therapeutic strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRx0237 (21, LMTX) is a tau aggregation inhibitor.465”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [465]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Also, tau pathology is likely to begin in EC then move to the hippocampus, and ultimately invading the cortex, following an overlapping path existing among functionally connected areas [55, 157, 158, 177].”
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · cited 3×
“Unfortunately, while the “Oligomer Hypothesis” is still a matter of investigation, and data are being gathered to test the grounds of its premises, the clinical failure of most of the anti-A (cid:2) drugs has strongly destabilized this concept.”
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“Second, we know since the 1990 s that there is no correlation between A (cid:2) deposition and clinical degree of dementia among affected individuals [25–28], and plaques might occur in the brains of individuals with no sign of dementia [27, 29, 30].”
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“This was predicted by a study showing that all of the soluble oligomers tested including β-synuclein, islet amyloid polypeptide, polyglutamine, lysozyme, human insulin, and prion peptide 106–126, display a common conformation-dependent structure that is unique to soluble oligomers [193], By now, a variety of studies h…”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“This temporal sequence derives from studies in patients with FAD, where the genetic-driven increase of Aβ is followed by NFT accumulation [194], whereas the increase of tau, as in tauopathies, is not associated with Aβ deposition.”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Cited by
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
“Research into Alzheimer’s disease has provided additional topical caveats (Gulisano et al., 2018; Hunter et al., 2018; Morris et al., 2018).”
BackgroundZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 358
“3 B) (Gulisano et al., 2018).”
Zhang, W., Xu, C., Sun, J., Shen, H.-M., Wang, J., & Yang, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.008 · Cited by 205
Novel target for treating Alzheimer’s Diseases: Crosstalk between the Nrf2 pathway and autophagy
Zhang, W., Feng, C., & Jiang, H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101207 · Cited by 198
Relationship Between Amyloid-β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer’s Disease
Wang, D., Chen, F., Han, Z., Yin, Z., Ge, X., & Lei, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.695479 · Cited by 197
The duality of amyloid-β: its role in normal and Alzheimer’s disease states
Azargoonjahromi, A. (2024) · Molecular Brain · doi:10.1186/s13041-024-01118-1 · Cited by 190
“Aβ accumulation is believed to initiate a cascade of events that lead to tau pathology [258].”
BackgroundCurrent and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo‐Minguez, A., Kenigsberg, P. A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 141
Koszła, O., & Sołek, P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01791-8 · Cited by 178
“The current global impact is staggering, with an estimated 46.8 million individuals affected, a figure projected to escalate to 131.5 million by 2050 [5].”
BackgroundInfluentialMicroglial activation states and their implications for Alzheimer's Disease
Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 199
Potential Bidirectional Relationship Between Periodontitis and Alzheimer’s Disease
Liccardo, D., Marzano, F., Carraturo, F., Guida, M., Femminella, G. D., Bencivenga, L., Agrimi, J., Addonizio, A., Melino, I., Valletta, A., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00683 · Cited by 156
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer's Disease · doi:10.1155/2022/9343514 · Cited by 115
“However, it is important to note that patients who have β-amyloid aggregates are more likely to have tau tangles [63].”
BackgroundThe Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)
Mroczko, B., Groblewska, M., & Litman‐Zawadzka, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194661 · Cited by 123
Gulisano, W., Melone, M., Ripoli, C., Tropea, M. R., Li Puma, D. D., Giunta, S., Cocco, S., Marcotulli, D., Origlia, N., Palmeri, A., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0163-19.2019 · Cited by 100
Self-citationNeuropathological assessment of the Alzheimer spectrum
Jellinger, K. A. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02232-9 · Cited by 89
Defective proteostasis in Alzheimer’s disease
Cozachenco, D., Ribeiro, F. C., & Ferreira, S. T. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101862 · Cited by 81
Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A., Lehmann, S., & Hirtz, C. (2024) · Brain Communications · doi:10.1093/braincomms/fcae396 · Cited by 101
“119 Nonetheless, the exact mechanisms underlying this relationship remain incompletely understood, and it is unclear whether this association exists independently of the amyloid plaques.”
Denver, P., & McClean, P. L. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238608 · Cited by 95
“…(AβOs) have been included in more recent revisions of the amyloid cascade hypothesis (Klein et al., 2001; Hardy and Selkoe, 2002), suggesting that soluble AβOs, rather than larger fibrils or plaques, elicit synaptic toxicity and memory dysfunction (Ferreira and Klein, 2011; Gulisano et al., 2018).”
BackgroundQi, Z., Huang, Z., Xie, F., & Chen, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27866 · Cited by 87
“Until now, there still is a lot unknown on the effect of Drp1 SUMOylation in the neural system (C. Guo et al., 2013; Martins, Tasca, & Cimarosti, 2016; Prudent et al., 2015; Wasiak, Zunino, & McBride, 2007).”
Qiu, W.-Q., Pan, R., Tang, Y., Zhou, X.-G., Wu, J.-M., Yu, L., Law, B. Y.-K., Ai, W., Yu, C.-L., Qin, D.-L., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110575 · Cited by 76
Genomics and Functional Genomics of Alzheimer's Disease
Kamboh, M. I. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01152-0 · Cited by 73
“and anti-tau therapies have been recommended to be used simultaneously [147] because both Aβ and tau may act in parallel to exert their detrimental effects on AD [148, 149].”
Luteolin for neurodegenerative diseases: a review
Jayawickreme, K., Ekwosi, C., Anand, A., Andres‐Mach, M., Właź, P., & Socała, K. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00610-8 · Cited by 80
“The mechanism of action was associated with the recovery of total phosphatase activity [ 70 ]. hyperphosphorylation, tangle formation, neuronal dysfunction, and finally symptom development [ 82].”
BackgroundMolecular Biomarkers in Neurological Diseases: Advances in Diagnosis and Prognosis
Myrou, A. D., Barmpagiannos, K., Ioakimidou, A., & Savopoulos, C. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052231 · Cited by 70
“Circulating biomarkers such as cell-free DNA (cfDNA), exosomal RNA, neurofilament light chain (NfL), and inflammatory cytokines have shown promise in tracking disease progression and response to treatment [8].”
InfluentialCell-type-directed network-correcting combination therapy for Alzheimer’s disease
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.035 · Cited by 74
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer’s disease
Tropea, M. R., Gulisano, W., Vacanti, V., Arancio, O., Puzzo, D., & Palmeri, A. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.022 · Cited by 55
Self-citationNam, Y., Shin, S. J., Kumar, V., Won, J., Kim, S., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00479-4 · Cited by 66
Tau is not necessary for amyloid-β–induced synaptic and memory impairments
Puzzo, D., Argyrousi, E. K., Staniszewski, A., Zhang, H., Calcagno, E., Zuccarello, E., Acquarone, E., Fa’, M., Li Puma, D. D., Grassi, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137040 · Cited by 53
Self-citationChami, M., & Checler, F. (2020) · Cells · doi:10.3390/cells9122577 · Cited by 56
Alkhalifa, A. E., Al-Ghraiybah, N. F., & Kaddoumi, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031914 · Cited by 56
“Tau, a microtubule-stabilizing protein, undergoes hyperphosphorylation, detaining from microtubules and forming intracellular NFTs [40,41].”
BackgroundTambini, M. D., Norris, K. A., & D'Adamio, L. (2020) · eLife · doi:10.7554/elife.52612 · Cited by 50
Self-citationIschemia as a common trigger for Alzheimer’s disease
Elman-Shina, K., & Efrati, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1012779 · Cited by 48
Stem Cell Therapy for Alzheimer’s Disease
Han, F., Bi, J., Qiao, L., & Arancio, O. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-4370-8_4 · Cited by 53
Self-citationMa, S., Zhou, X., Wang, Y., Li, Z., Wang, Y., Shi, J., & Guan, F. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102325 · Cited by 45
Yonamine, C. Y., Michalani, M. L. E., Moreira, R. J., & Machado, U. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216480 · Cited by 54
“…activation anteceded NTFs in a mouse model of tauopathy [12], (2) synaptic and memory impairments are not mediated by NFTs [13], and (3) insoluble deposition of tau may be a compensatory protective mechanism [13], compromise the proposal of tauopathy as the main player in AD pathogenesis [13].”
BackgroundNeuropathology of the Alzheimer's continuum: an update
Jellinger, K. A. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3050 · Cited by 84
“lar Aβ and tau act in parallel and upstream of APP [175, 176].”
Kurhaluk, N., Kamiński, P., Bilski, R., Kołodziejska, R., Woźniak, A., & Ткаченко, Г. М. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083658 · Cited by 58
“A common pathological feature of these disorders is the aggregation of misfolded proteins, including β -amyloid and tau in AD [152], α -synuclein in Parkinson’s disease [153], and huntingtin in Huntington’s disease [154].”
Tau Related Pathways as a Connecting Link between Epilepsy and Alzheimer’s Disease
Paudel, Y. N., Angelopoulou, E., Jones, N. C., O'Brien, T. J., Kwan, P., Piperi, C., Othman, I., & Shaikh, M. F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00460 · Cited by 44
Advances in Proteasome Enhancement by Small Molecules
George, D. E., & Tepe, J. J. (2021) · Biomolecules · doi:10.3390/biom11121789 · Cited by 51
Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
Panza, F., Lozupone, M., Watling, M., & Imbimbo, B. P. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621751 · Cited by 41
“We cannot exclude the possibility that in AD patients the accumulation of Aβ in the brain is secondary to an unknown initial disrupting event [38,39], including viral or microbial infection [40].”
BackgroundGuo, Q., Li, Y., Xu, S., Wang, P., Qian, K., Yang, P., Sheng, D., Wang, L., Cheng, Y., Meng, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.074 · Cited by 40
Afsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 49
“The soluble forms of Aβ and tau are also found to be increased in the brains of AD patients [25].”
BackgroundAbbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 51
“These tangles obstruct axonal transport, starving presynaptic terminals of essential proteins, lipids, and mitochondria [220, 221].”
Therapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment
Atlante, A., Amadoro, G., Latina, V., & Valenti, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226742 · Cited by 41
“More recently, an alternative and not mutually exclusive “dual-hit hypothesis” has been proposed by which Aβ and Tau are partners in crime by cooperating in damaging the synapses, thus resulting in memory loss and “dying back” neuronal death [15].”
Tapia-Arellano, A., Cabrera, P., Cortés-Adasme, E., Riveros, A. L., Hassan, N., & Kogan, M. J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02526-0 · Cited by 45
“In fact, there are more evidence that show the key role of Tau as an active agent, refuting the Amyloid cascade as the main and unique actor of neurodegeneration[15, 20], and turning the focus on AD research field.”
BackgroundTropea, M. R., Li Puma, D. D., Melone, M., Gulisano, W., Arancio, O., Grassi, C., Conti, F., & Puzzo, D. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102154 · Cited by 39
Self-citationMarcatti, M., Fracassi, A., Montalbano, M., Natarajan, C., Krishnan, B., Kayed, R., & Taglialatela, G. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04255-9 · Cited by 38
Yin, Z., Hua, L., Chen, L., Hu, D., Li, J., An, Z., Tian, T., Ning, H., & Ge, Y. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104911 · Cited by 39
Patel, J. C., Shukla, M., & Shukla, M. (2025) · Cells · doi:10.3390/cells14120918 · Cited by 48
Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis
Vegas‐Suárez, S., Simón, J., Martínez‐Chantar, M. L., & Moratalla, R. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.864263 · Cited by 40
Joshi, N. J., & Alavala, R. R. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101500 · Cited by 41
Gabrielli, M., Tozzi, F., Verderio, C., & Origlia, N. (2022) · Cells · doi:10.3390/cells12010063 · Cited by 36
“Notably, APP has been reported as necessary for Aβ and tau oligomers to enter the neurons and induce abnormal synaptic function and memory [41,186].”
BackgroundGong, B., Zhang, W., Cong, W., Gu, Y., Ji, W., Yin, T., Zhou, H., Hu, H., Zhuang, J., Luo, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400149 · Cited by 44
Zimmer‐Bensch, G., & Zempel, H. (2021) · Cells · doi:10.3390/cells10113064 · Cited by 34
“This is commonly placed as the upstream event in disease, but this amyloid hypothesis is heavily debated for 30 years [6,7].”
BackgroundSingh, K., Gupta, J. K., Kumar, S., & Soni, U. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037275221240327042353 · Cited by 36
Xu, J., Gao, C., Zhang, J., Lu, J., Xuan, Y., Wang, S., & Bu, C. (2025) · Molecular Imaging · doi:10.1177/15353508251393056 · Cited by 36
“83 In PD, the loss of dopaminergic neurons in the substantia nigra and the deposition of Lewy bodies formed by α -synuclein are early signs, often visible as a decline in DAT function in the striatum.”
Macromolecular Structures and Proteins Interacting with the Microtubule Associated Tau Protein
Jiménez, J. S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.023 · Cited by 31
Sugandhi, V. V., Gadhave, D. G., Ugale, A. R., Kulkarni, N. N., Nangare, S., Patil, H. P., Rath, S., Saxena, R., Lavate, A., Patel, A. T., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102775 · Cited by 35
“However, A β accumulation in the brain is proposed to be an early toxic event in the pathogenesis of AD (Gulisano et al., 2018; Y. Zhang et al., 2023).”
del Cerro, I., Villarreal, M. F., Abulafia, C., Duarte-Abritta, B., Sánchez, S. M., Castro, M. N., Bocaccio, H., Ferrer, I., Menchón, J. M., Sevlever, G. E., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.01.018 · Cited by 29
Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses
Kadamangudi, S., Marcatti, M., Zhang, W.-R., Fracassi, A., Kayed, R., Limon, A., & Taglialatela, G. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02839-2 · Cited by 25
Cocco, S., Rinaudo, M., Fusco, S., Longo, V., Gironi, K., Renna, P., Aceto, G., Mastrodonato, A., Puma, D. D. L., Podda, M. V., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00541 · Cited by 28
Self-citationExploring the Comprehensive Neuroprotective and Anticancer Potential of Afzelin
Kciuk, M., Garg, N., Dhankhar, S., Saini, M., Mujwar, S., Devi, S., Chauhan, S., Singh, T. G., Singh, R., Marciniak, B., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060701 · Cited by 32
“The presence of these aggregates hinders the transmission of brain signals and induces an inflammatory response, both of which are implicated in the development of cognitive dysfunction [4,5].”
BackgroundUiO-66-NH 2 Metal–Organic Framework for the Detection of Alzheimer’s Biomarker Aβ (1-42)
Fan, Q., Wang, J., Biazik, J. M., Geng, S., Mazur, F., Li, Y., Ke, P. C., & Chandrawati, R. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00768 · Cited by 25
Munteanu, C., Iordan, D. A., Hoteteu, M., Popescu, C., POSTOIU, R. L., Onu, I., & Onose, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015481 · Cited by 24
“H 2 S emerges as a biochemically potent molecule capable of influencing A β and tau, as well as vascular pathology—a fact that has hitherto been underrepresented in the conventional academic discourse on AD [162].”
BackgroundSchmidt-Morgenroth, I., Michaud, P., Gasparini, F., & Avraméas, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310523 · Cited by 27
“Aβ accumulation has been studied as the first driver of AD and as possibly causing inflammation and tauopathy [41].”
BackgroundLiu, N., Haziyihan, A., Zhao, W. G., Chen, Y., & Chao, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00434-9 · Cited by 28
Zarini-Gakiye, E., Amini, J., Sanadgol, N., Vaezi, G., & Kazem, P. (2020) · Current Molecular Pharmacology · doi:10.2174/1874467213666200422090135 · Cited by 22
Role and Functions of Irisin: A Perspective on Recent Developments and Neurodegenerative Diseases
Minuti, A., Raffaele, I., Scuruchi, M., Lui, M., Muscarà, C., & Calabrò, M. (2025) · Antioxidants · doi:10.3390/antiox14050554 · Cited by 31
Godyń, J., Zaręba, P., Łażewska, D., Stary, D., Reiner‐Link, D., Frank, A., Latacz, G., Mogilski, S., Kaleta, M., Doroż-Płonka, A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105129 · Cited by 21
Dhiman, N., Deshwal, S., Rishi, V., Singhal, N. K., & Sandhir, R. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115034 · Cited by 23
Yao, W., Tambini, M. D., Liu, X., & D'Adamio, L. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0207-19.2019 · Cited by 20
“…and prompts deficits in synaptic plasticity (Puzzo and Arancio, 2006; Shankar et al., 2007; Puzzo et al., 2008, 2017; Fogel et al., 2014; Gulisano et al., 2018). sAPP has neurotrophic functions and is involved in synaptic plasticity (Milosch et al., 2014). sAPP promotes axon pruning and…”
Self-citationZhu, X., Dai, W.-Z., & Ma, T. (2020) · BMC Medical Genetics · doi:10.1186/s12881-020-01114-x · Cited by 23
“As well known, accumulation of Aβ in brain is one important pathological hallmark of AD, moreover, it is considered to induce a deleterious neurodegenerative cascade and finally cause cognitive impairments [18].”
Non-Canonical Roles of Tau and Their Contribution to Synaptic Dysfunction
Siano, G., Falcicchia, C., Origlia, N., Cattaneo, A., & Primio, C. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810145 · Cited by 23
“However, Tau can form not only insoluble deposits but it is also present as non-fibrillar soluble monomeric and oligomeric species that have been found to increase in the brain of AD patients [92,93].”
BackgroundZhu, G., Yuan, F., Cui, X., Jia, R., Kang, X., & Zhao, R. Z. (2021) · Journal of Natural Medicines · doi:10.1007/s11418-021-01574-2 · Cited by 20
Meng, Y., Kalia, L. V., Kalia, S. K., Hamani, C., Huang, Y., Hynynen, K., Lipsman, N., & Davidson, B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060719 · Cited by 30
“This is further challenged by remaining uncertainties, regarding whether reductions in A β will translate into improved cognition [50].”
BackgroundBlood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review
Liampas, I., Kyriakoulopoulou, P., Karakoida, V., Kavvoura, P. A., Sgantzos, M. N., Bogdanos, D. P., Stamati, P., Dardiotis, E., & Siokas, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111838 · Cited by 25
“Amyloid-β and hyperphosphorylated tau deposits primarily in the temporal and parietal lobes are crucial in the cascade of AD-related neurodegeneration [29].”
BackgroundPan, T.-T., Sun, Y., Shi, Y.-F., Zhao, M., Khan, N. U., Chen, H., Ji, W., Li, J., Han, L., & Ma, Q. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01840-5 · Cited by 21
“Its major pathological features include the accumulation of amyloid-β (A β ) peptides, with particular pathological contributions from neurotoxic A β , and intracellular tau-containing neurofibrillary tangles [1, 2].”
Edwards, N. C., Lao, P. J., Alshikho, M. J., Mazen, J., Huber, B. D., Hale, C., Berroa, J., Morel, N., Pacheco, A., Walker, S., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000214220 · Cited by 21
Tau proteins and senescent Cells: Targeting aging pathways in Alzheimer’s disease
Singh, M., Ali, H., Jyothi, S. R., Kaur, I., Kumar, S., Sharma, N., Prasad, G. V. S., Pramanik, A., Almalki, W. H., & Imran, M. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149165 · Cited by 18
Basurto‐Islas, G., Diaz, M. C., Zavala-Ocampo, L. M., Martínez‐Herrera, M., & López-Camacho, P. Y. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400721 · Cited by 21
Yonamine, C. Y., Passarelli, M., Suemoto, C. K., Pasqualucci, C. A., Filho, W. J., Alves, V. A. F., Marie, S. K. N., Corrêa‐Giannella, M. L., Britto, L. R., & Machado, U. F. (2023) · Cells · doi:10.3390/cells12091250 · Cited by 20
“The amyloid hypothesis is a classical theory to explain the mechanisms involved in AD neurodegeneration; however, several efforts aiming to reduce amyloid beta protein accumulation have failed to promote some significant clinical benefits in patients with AD [2,3].”
BackgroundAbdollahi, Z., Nejabat, M., Abnous, K., & Hadizadeh, F. (2024) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.394816 · Cited by 23
“Accumulations of pathological tau protein in synapses, along with the aggregation of Aβ into amyloid plaques, is the main pathological hallmark in AD, which leads to the damage and destruction of synapses resulting in impairment of memory and cognition (44,45).”
BackgroundLv, J., Chen, L., Zhu, N., Sun, Y., Pan, J., Gao, J., Liu, J., Liu, G., & Tao, Y. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00613-3 · Cited by 18
O’Day, D. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021393 · Cited by 18
Detecting Abnormal Behaviors in Dementia Patients Using Lifelog Data: A Machine Learning Approach
Kim, K., Jang, J., Park, H., Jeong, J., Shin, D., & Shin, D. (2023) · Information · doi:10.3390/info14080433 · Cited by 18
Functional nanoparticle-enabled non-genetic neuromodulation
Zhang, Z., You, Y., Ge, M., Lin, H., & Shi, J. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02084-x · Cited by 22
“Traditional treatments of neurological illnesses are rather unsatisfactory, which in most cases only perform limited effectiveness for certain symptoms without stopping the deterioration of the conditions while result in side-effects, especially in curing common neurodegenerative disorders like Parkinson’s disease (PD…”
BackgroundProtective Role of Electroacupuncture Against Cognitive Impairment in Neurological Diseases
Xin, Y., Zhou, S., Chu, T., Zhou, Y., & Xu, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22999240209102116 · Cited by 19
TREM2 in neurodegeneration and diseases
Abdulkhaliq, A. A., Alasiri, G., Kim, B., Khan, J., Ajoolabady, A., Yousof, S. M., Ren, J., Tuomilehto, J., Borai, A., Alrfaei, B. M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03505-7 · Cited by 16
“AD is a progressive neurodegeneration characterized by formation of interneuronal amyloid-β (A β ) plaques and intraneur-onal neuro fi brillary tau tangles, leading to synaptic dysfunction, neuronal cell death, ultimately, cognitive impairment and dementia [20 – 22].”
Intersection of H2S and Nrf2 signaling: Therapeutic opportunities for neurodegenerative diseases
Soni, P., Paswan, S. K., Paul, B. D., & Thomas, B. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00627 · Cited by 19
“In AD, the pathological accumulation of amyloid-beta (A β ) plaques and hyperphosphorylated tau tangles triggers neurotoxicity and actively disrupts cellular antioxidant defense systems [28,29].”
Biembengut, Í. V., Silva, I. L. Z., de Souza, T. D. A. C. B., & Shigunov, P. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06585-6 · Cited by 17
Jiao, F., Jiang, D., Li, Y., Mei, J., Wang, Q., & Li, X. (2022) · Cells · doi:10.3390/cells11203201 · Cited by 17
Lou, T.-W., Tao, B., & Chen, M. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.01.032 · Cited by 21
Bir, A., Ghosh, A., Chauhan, A., Saha, S., Saini, A. K., Bisaglia, M., & Chakrabarti, S. (2024) · Antioxidants · doi:10.3390/antiox13030316 · Cited by 20
“Exosomes secreted by neurons and glial cells have also been shown to contain A β peptides and Tau protein [119,120] and may contribute to the spread of AD pathology throughout the brain.”
Wu, C., Zou, P., Zhu, L., Feng, S., Deng, Q., Liu, T. C., Duan, R., & YANG, L. (2025) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003650 · Cited by 18
“Moreover, ample evidence shows that the central role of A β plaques and tau tangles in AD pathogenesis contributes to synaptic dysfunction and neuronal loss (25,26).”
Yildiz, C. B., & Zimmer‐Bensch, G. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11454-0_15 · Cited by 19
Kuziak, A., Heczko, P. B., Pietrzyk, A., & Strus, M. (2025) · Microorganisms · doi:10.3390/microorganisms13010122 · Cited by 15
“However, AD tau is hyperphosphorylated, leading to tau protein aggregation and twisted filament formation [9,10].”
Chakraborty, A., Sami, S. A., & Marma, K. K. S. (2021) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-021-00081-w · Cited by 20
“However, abnormal phosphorylation of tau induces the accumulation of insoluble tau aggregates and demonstrated the presence of eight phosphates per molecule of tau in the AD brain [21].”
BackgroundSignal Pathways and Intestinal Flora through Trimethylamine N-oxide in Alzheimer's Disease
Zhang, Y., & Jian, W. (2023) · Current Protein and Peptide Science · doi:10.2174/1389203724666230717125406 · Cited by 14
Ramakrishnan, P., Joshi, A., Fazil, M., & Yadav, P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122334 · Cited by 13
Mathes, T. G., Monirizad, M., Ermis, M., de Barros, N. R., Rodriguez, M., Kraatz, H., Jucaud, V., Khademhosseini, A., & Falcone, N. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.05.020 · Cited by 18
Metadata
- Authors
- Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., Puzzo, D., & Arancio, O.
- Affiliations
- University of Catania (IT)
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, USA
- Columbia University (US)
- Università Cattolica del Sacro Cuore (IT)
- Department of Pharmacology, Physiology and Neuroscience, Rutgers University, Newark, NJ, USA
- Corresponding author
- Puzzo, Daniela
- Arancio, Ottavio
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S611-S631
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC8371153
- OpenAlex
- W2807540667
- Cited by
- 313
- References
- 223
- Citations by year
- 2026: 59 · 2025: 92 · 2024: 60 · 2023: 32 · 2022: 23 · 2021: 17 · 2020: 18 · 2019: 10 · 2018: 2
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- Funders
- National Institute on Aging (R01AG049402, R01AG017761)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Humans, Signal Transduction, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.